IDT and Elegen Integrated DNA Technologies (IDT), a global leader in genomics solutions, has announced a strategic partnership with Elegen, a pioneer in next-generation DNA manufacturing. This collaboration aims to revolutionize the long DNA synthesis market by offering researchers rapid, cost-effective access to high-quality, high-complexity clonal gene synthesis services through Elegen’s ENFINIA™ Plasmid DNA technology.
Expanding Access to High-Quality Long DNA Synthesis
For the first time, IDT and Elegencustomers will have the opportunity to access Elegen’s ENFINIA™ Plasmid DNA, a long and high-complexity clonal gene synthesis service. This innovative solution enables the synthesis of NGS-verified clonal genes ranging from 5 kb to 15 kb, a capability that has historically been challenging to achieve with traditional DNA synthesis technologies. By leveraging Elegen’s cutting-edge manufacturing processes, IDT and Elegen customers will benefit from a streamlined workflow that delivers these synthetic genes in as fast as 10 business days, significantly accelerating research timelines.
The ENFINIA™ platform provides enhanced reliability and precision in gene synthesis, ensuring high fidelity and consistency. By integrating Elegen’s proprietary technology with IDT’s established synthetic biology portfolio, this partnership offers a comprehensive solution that meets the growing demand for high-quality, long DNA sequences in various research applications, including gene therapy, synthetic biology, and biopharmaceutical development.
Strengthening IDT’s Synthetic Biology Portfolio
This collaboration marks another milestone in IDT’s continuous expansion and innovation within the synthetic biology sector. Over the past 12 months, IDT and Elegen has significantly enhanced its synthetic biology offerings, introducing new products and expanding its U.S. facility to increase throughput and operational efficiency.
IDT’s synthetic biology portfolio already includes an extensive range of gene and gene fragment solutions, such as:
- Rapid Genes: High-quality, sequence-verified synthetic genes available in a short turnaround time.
- Custom Vectors and Plate Formats: Tailored solutions designed to accommodate high-throughput workflows.
- Custom Solutions Support: Expert guidance from a team of leading scientists and synthetic biology specialists.
By incorporating Elegen’s ENFINIA™ Plasmid DNA into its suite of offerings, IDT and Elegen strengthens its position as a market leader, providing researchers with even greater flexibility, speed, and accuracy in synthetic gene synthesis.
Industry Leaders Emphasize the Impact of the Partnership
Sandy Ottensmann, Vice President and General Manager of the Gene Writing & Editing Business Unit at IDT, highlighted the strategic importance of this partnership:
“IDT and Elegen has continued to bolster its synthetic biology offerings and capabilities with new products and enhancements, as well as a U.S. facility expansion, to boost our throughput and efficiency over the last 12 months. Our partnership with Elegen allows us to offer customers competitively priced long and complex DNA that they can pair with IDT’s extensive portfolio of custom synthetic biology solutions.”
Echoing this sentiment, Matthew Hill, PhD, Founder and CEO of Elegen, emphasized the transformational potential of the collaboration:
“We are thrilled to partner with IDT, a long-standing leader in DNA synthesis. This collaboration allows Elegen to expand access to our ENFINIA™ Plasmid DNA and equip researchers with rapid access to longer and more complex DNA sequences—capabilities that have historically been limited in the market. We believe this partnership will accelerate research and development across the industry, driving innovation and breakthroughs in the life sciences.”
Driving Innovation in DNA Synthesis for Life Sciences
Long and complex DNA sequences are critical in various fields of biomedical research, including genetic engineering, precision medicine, vaccine development, and synthetic biology. However, traditional DNA synthesis techniques often struggle with efficiency and scalability when working with sequences longer than 5 kb.
The IDT-Elegen partnership directly addresses these challenges by providing researchers with a powerful alternative that combines speed, scalability, and cost-effectiveness. By offering long, high-complexity clonal gene synthesis services, the partnership empowers scientists to pursue ambitious research projects with unprecedented efficiency and accuracy.
A Game-Changer for the Synthetic Biology Market
The demand for long DNA synthesis is growing rapidly as advancements in synthetic biology, gene therapy, and biopharmaceuticals drive the need for precise and reliable gene assembly. By combining Elegen’s breakthrough ENFINIA™ Plasmid DNA technology with IDT’s synthetic biology expertise, this partnership delivers a cutting-edge solution that aligns with the evolving needs of the life sciences community.
With this partnership, IDT and Elegen are not only expanding their market presence but also shaping the future of genetic engineering by making long DNA synthesis more accessible, scalable, and efficient. This collaboration is poised to become a game-changer for researchers, unlocking new possibilities in molecular biology, synthetic biology, and genetic engineering.
A New Era in Synthetic Biology
As the synthetic biology industry continues to evolve, the demand for high-quality, long DNA synthesis solutions will only increase. The partnership between IDT and Elegen represents a pivotal moment in the field, offering researchers an unparalleled combination of speed, precision, and reliability in synthetic gene synthesis.
By integrating Elegen’s ENFINIA™ Plasmid DNA into IDT’s already robust synthetic biology portfolio, this collaboration ensures that scientists and researchers have access to the most advanced DNA synthesis technologies available today. With faster turnaround times, enhanced accuracy, and scalable solutions, IDT and Elegen are paving the way for groundbreaking discoveries that will drive the future of genomics and biotechnology forward.
